Cobra Biologics Ltd and Recopharma have announced an agreement to supply a human Fc fusion protein using Cobra’s maxXpress service.
Cobra Biologics will apply its cost-effective maxXpress platform service to deliver a programme of vector construction using the UCOE technology, transfectant pool generation, and supply, purification and protein characterization.
The service allows Recopharma to form a quick and reliable assessment on the specific expertise of Cobra’s cell line development and analytical scientist teams.
Recopharma has developed a unique technology that uses mucins, naturally occurring proteins produced by epithelial tissues with many potential applications.
The FC fused mucins will provide a natural alternative to ocular lubricants and tear substitutes that are at present available and set to be used as a treatment and prophylactic that tackles viral conjunctivitis.
Peter Coleman CEO of Cobra Biologics commented: “I am very pleased that Recopharma has chosen Cobra to supply pre-clinical material. Cobra’s maxXpress service has proven very popular with customers. Indeed, the service allows customers to make a fast assessment as to whether the UCOE technology and cell development team are the best combination to take their protein forward to clinical trials”.
Jan Holgersson, CEO/ CSO of Recopharma said “We are very excited about working with Cobra Biologics, and to apply their cell line development expertise on our mucin-type fusion proteins. A cell pool providing good yields will be an important commercial milestone on our path towards clinical studies with our dry eye disease lead compound.”